FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

washington,	D.C.	20549	

***doffinigton, 5.5. 200-75	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		
	Estimated average burden			

hours per response:

0.5

Check this box if no longer subject t	ı
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kaufman David Ross</u>					2. Issuer Name and Ticker or Trading Symbol HOOKIPA Pharma Inc. [HOOK]								Relationship heck all appl	icable) or	ng Per	10% Ov	vner	
(Last) (First) (Middle) C/O HOOKIPA PHARMA INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/01/2021								Office below	r (give title)		Other (s below)	specify	
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) NEW YO	ORK N	Υ :	10118								X Form	,						
(City)	(St	tate) (Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				ransaction e onth/Day/Ye	Execution Date		, Transaction Disposed Code (Instr. 5)		ities Acquired (A) o		Benefic	es Form ially (D) of Following (I) (II		n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	v	Amount	(A) or (D)		Transac (Instr. 3	tion(s)			,,			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (ransaction (code (Instr. I)		tive ties ed sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e S Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$16.61	06/01/2021		A		9,600		(1)	06	5/01/2031	Common Stock	9,600	\$0	9,600		D		

Explanation of Responses:

1. This option shall vest and become fully exercisable on June 1, 2022.

/s/ Reinhard Kandera, as Attorney-in-Fact

06/04/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).